Cityscape: Tiragolumab Plus Atezolizumab For Non-Small Cell Lung Cancer

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

CITYSCAPE: 1L tiragolumab + atezolizumab vs placebo + atezolizumab in PD-L1-selected NSCLC

CITYSCAPE: tiragolumab in NSCLC

Dr Melissa Johnson: Tiragolumab Plus Atezolizumab Improves Objective Response in CITYSCAPE Trial

Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

NSCLC highlights at ASCO 2020

ASCO Lung Cancer Roundtable - NSCLC - The CITYSCAPE Trial: Anti TIGIT & Immune Checkpoint Inhibitor

GRACE - Global Resource for Advancing Cancer Education

Tiragolumab and atezolizumab in metastatic esophageal cancer

Dr Chitresh Aggarwal | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a 1L

CRSF - Cancer Research and Statistic Foundation

Adjuvant atezolizumab in NSCLC

Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer

FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC

Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope

Society for Immunotherapy of Cancer

First-line atezolizumab plus chemotherapy improves survival in lung cancer patients

infocusrx today

Atezolizumab’s Role in Treating Nondriver NSCLC

Targeted Oncology

Neoadjuvant atezolizumab in NSCLC

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

Immunotherapy in second-line treatment of non-small cell lung cancer

IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

Assessing the impact of atezolizumab in NSCLC